Efficacy of Pravastatin Monotherapy in Patients with Hypercholesterolemia.
10.4070/kcj.1992.22.1.130
- Author:
Jae Joong KIM
;
Jae Kwan SONG
;
Seong Wook PARK
;
Su Kil PARK
;
Seung Jung PARK
;
Simon Jong LEE
- Publication Type:Original Article
- Keywords:
Hypercholesterolemia;
Pravastatin
- MeSH:
Apolipoprotein A-I;
Apolipoproteins;
Cholesterol;
Creatinine;
Diet Therapy;
Drug Therapy;
Fasting;
Follow-Up Studies;
Humans;
Hypercholesterolemia*;
Lovastatin;
Middle Aged;
Oxidoreductases;
Pravastatin*;
Simvastatin;
Triglycerides;
Uric Acid
- From:Korean Circulation Journal
1992;22(1):130-139
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The HMG-CoA reductase inhibitor is the most powerful cholesterol lowering drug and lovastatin, simvastatin and pravastatin are used clinically. We studied the efficacy and side effects of pravastatin monotherapy in patients with hypercholesterolemia(type IIa or IIb). METHODS: Patients who showed 12-hours fasting serum total cholesterol level more than 240mg% were enrolled to diet therapy. After 4weeks of diet therapy, serum lipid profiles were checked and the drug therapy was considered according to NCEP guidelines. The pravastatin 5mg po bid was administrated and the patients had regular follow-up every 2weeks for 8week. RESULTS: The total study population was 20 patients and the mean age of them was 55 years old (55+/-18, M : F=6 : 14). There were a few side effects in 5% of study patients and no patient discontinued pravastatin due to side effects.The side effect was G-I trouble and there were not other side effects. Serum CK was elevated in only one patient but the elevation was mild(less than 3 times) and transient. The LFT, serum uric acid, BUN and creatinine level did not show any significant changes during therapy. Among lipid profiles, total cholesterol, LDL-cholesterol and apolipoprotein B level showed significant reduction after therapy and the maximum reduction was achieved after 2week of therapy. The mean reduction was 20%, 33% and 23% respectively. HDL-cholesterol and apolipoprotein A1 11% and 17% respectively. The triglyceride level did not show any changes during therapy but in one type IIb patient, the triglyceride level decreased significantly. CONCLUSIONS: The pravastatin is effective and safe in patients with hypercholesterolemia.
